Showing 1 - 3 results of 3 for search 'Mark S Cragg', query time: 0.01s Refine Results
  1. 1
    FcγRII (CD32) modulates antibody clearance in NOD SCID mice leading to impaired antibody-mediated tumor cell deletion

    FcγRII (CD32) modulates antibody clearance in NOD SCID mice leading to impaired antibody-mediated tumor cell deletion by Robert J Oldham, C Ian Mockridge, Sonya James, Patrick J Duriez, H T Claude Chan, Kerry L Cox, Vicentiu A Pitic, Mark S Cragg

    Published 2020-05-01
    Get full text
    Article
    Save to List
    Saved in:
  2. 2
    Downhill running does not alter blood C1q availability or complement-dependent cytotoxicity of therapeutic monoclonal antibodies against haematological cancer cell lines in vitro

    Downhill running does not alter blood C1q availability or complement-dependent cytotoxicity of therapeutic monoclonal antibodies against haematological cancer cell lines in vitro by Harrison D. Collier-Bain, Frankie F. Brown, Adam J. Causer, Lois Ross, Daniela Rothschild-Rodriguez, Noah Browne, Rachel Eddy, Kirstie L. Cleary, Juliet C. Gray, Mark S. Cragg, Sally Moore, James Murray, James E. Turner, John P. Campbell

    Published 2024-11-01
    Get full text
    Article
    Save to List
    Saved in:
  3. 3
    Domain binding and isotype dictate the activity of anti-human OX40 antibodies

    Domain binding and isotype dictate the activity of anti-human OX40 antibodies by C Ian Mockridge, Kerry L Cox, Martin J Glennie, Mark S Cragg, Monika Semmrich, Linda Mårtensson, Ingrid Teige, Jordana Griffiths, Khiyam Hussain, Hannah L Smith, Theodore Sanders, Jinny Kim, Tatyana Inzhelevskaya, Chris A Penfold, Alison L Tutt, HT Claude Chan, Vikki English, Ruth F French, Aymen Al-Shamkhani, Bjorn L Frendeus, Jane E Willoughby

    Published 2020-10-01
    Get full text
    Article
    Save to List
    Saved in:

Search Tools: